State-level variations in the utilization of lung cancer screening among fee-for-service Medicare beneficiaries: an analysis of the 2015-2017 Physician and Other Supplier data.
Lung cancer screen (LCS) is an important secondary prevention measure to reduce lung cancer mortality. We aim to assess state-level variations in LCS among the US elderly during the first three years since Medicare began its LCS reimbursement policy in 2015. This ecological study examined the relationships between LCS utilization density, defined as the number of low-dose computed tomography (LDCT) or shared decision making and counseling (SDMC) per 1000 fee-for-service (FFS) Medicare beneficiaries derived from the Medicare Provider Utilization and Payment Data: Physician and Other Supplier Public Use File, and state-level factors from several publicly available data sources, using Kruskal-Wallis tests and cluster analysis. In 2017, the median utilization density per 1000 FFS beneficiaries was 3.32 for LDCT and 0.46 for SDMC, which was 24 and 13 times the 2015 level, respectively. From 2015 to 2017, the total number of unique providers billed for LCS increased from 222 to 3444 for LDCT and from 20 to 523 for SDMC. Higher utilizations for both LDCT and SDMC tended to concentrate in the northeastern and upper Midwest states than southwest states. The cluster of states with high utilization density was not those with the most lung cancer mortality and/or smoking prevalence. We found a steady increase in LCS utilization since Medicare began its reimbursement policy. The utilization and its growth varied across the US states and differed between LDCT and SDMC, indicating large growth potentials for LCS and for states with high lung cancer mortality and smoking prevalence.